Review





Similar Products

compound 56  (Glen Research)
86
Glen Research compound 56
Compound 56, supplied by Glen Research, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/56+compound/us12509684-1944-0-6
Average 86 stars, based on 1 article reviews
compound 56 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
compound 56  (Array BioPharma)
90
Array BioPharma compound 56
Compound 56, supplied by Array BioPharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/compound+56/pm40347791-151-16-9
Average 90 stars, based on 1 article reviews
compound 56 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
compounds 55 56  (ATCC)
94
ATCC compounds 55 56
Compounds 55 56, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/55-2/pmc12818766-259-12-57
Average 94 stars, based on 1 article reviews
compounds 55 56 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
compound 56 (fig. 5) containing pyrazolo-pyridazine structure  (Syngenta)
90
Syngenta compound 56 (fig. 5) containing pyrazolo-pyridazine structure
Compound 56 (Fig. 5) Containing Pyrazolo Pyridazine Structure, supplied by Syngenta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/compound+56++fig++5++containing+pyrazolo+pyridazine+structure/pm39724455-97-10-3
Average 90 stars, based on 1 article reviews
compound 56 (fig. 5) containing pyrazolo-pyridazine structure - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
compound 56  (Syngenta)
90
Syngenta compound 56
Compound 56, supplied by Syngenta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/compound+56/pm39724455-97-3-3
Average 90 stars, based on 1 article reviews
compound 56 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
compound 56  (Merck & Co)
90
Merck & Co compound 56
A Bars represent LDH release at 20 hours after exposure to zinc (40 µM), with or without EGF (100 ng/ml), methyl-beta-cyclodextrin (MβCD, 2 mM; caveolin-dependent endocytosis inhibitor), chlorpromazine (CP, 2 µM; clathrin-dependent endocytosis inhibitor), compound 56 <t>(Cpd56,</t> 1 µM; inhibitor of EGFR tyrosine kinase activity), or ciliobrevin A (ciliob, 500 nM; dynein inhibitor) (mean ± SEM, n = 3-15 taken from ≥3 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or not significant (ns) for zinc, and ** p < 0.01 or *** p < 0.001 for Zn + EGF, analyzed using ANOVA with Dunnett’s post-hoc test). B Western blot analysis (upper) and quantitative graphs (lower) demonstrate the protein levels of EGFR and LAMP-1 at 0.5 hours after EGF (100 ng/ml) treatment with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The bar graphs indicate the band density ratio of EGFR or LAMP-1 to Actin (mean ± SEM, n = 4–8 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or ### p < 0.001 for control , and * p < 0.05 or ** p < 0.01 for EGF, analyzed by ANOVA using Dunnett’s post-hoc test). C Microscopic images (left) and quantitative graphs (right) show LTR-labeled neuronal cells at 1 h after EGF (100 ng/ml) treatment, with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). Scale bar: 100 µm. The bar graphs represent LTR intensity measured using the Image J program (mean ± SEM, n = 9 or 15 different fields taken from ≥4 independent biological replicate experiments, ## p < 0.01 or #### p < 0.0001 for control, and ** p < 0.01 for EGF, analyzed by ANOVA with Dunnett’s post-hoc test). D Western blot analysis demonstrates the release of cathepsin B (CTSB) from lysosomes to the cytosol. Cytosolic proteins were extracted at 6 h after exposure to 40 µM zinc with or without EGF (100 ng/ml), MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The lower bar graph presents the band intensity ratio of mature CTSB to Actin (mean ± SEM, n = 6 or 3 independent biological replicate experiments, # p < 0.05, or #### p < 0.0001 for zinc, and * p < 0.05, ** p < 0.01, or **** p < 0.0001 for Zn + EGF, analyzed by ANOVA using Dunnett’s post-hoc test).
Compound 56, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/cpd56/pmc11560978-332-20-23
Average 90 stars, based on 1 article reviews
compound 56 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
compound 56  (Mcule Inc)
90
Mcule Inc compound 56
A Bars represent LDH release at 20 hours after exposure to zinc (40 µM), with or without EGF (100 ng/ml), methyl-beta-cyclodextrin (MβCD, 2 mM; caveolin-dependent endocytosis inhibitor), chlorpromazine (CP, 2 µM; clathrin-dependent endocytosis inhibitor), compound 56 <t>(Cpd56,</t> 1 µM; inhibitor of EGFR tyrosine kinase activity), or ciliobrevin A (ciliob, 500 nM; dynein inhibitor) (mean ± SEM, n = 3-15 taken from ≥3 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or not significant (ns) for zinc, and ** p < 0.01 or *** p < 0.001 for Zn + EGF, analyzed using ANOVA with Dunnett’s post-hoc test). B Western blot analysis (upper) and quantitative graphs (lower) demonstrate the protein levels of EGFR and LAMP-1 at 0.5 hours after EGF (100 ng/ml) treatment with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The bar graphs indicate the band density ratio of EGFR or LAMP-1 to Actin (mean ± SEM, n = 4–8 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or ### p < 0.001 for control , and * p < 0.05 or ** p < 0.01 for EGF, analyzed by ANOVA using Dunnett’s post-hoc test). C Microscopic images (left) and quantitative graphs (right) show LTR-labeled neuronal cells at 1 h after EGF (100 ng/ml) treatment, with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). Scale bar: 100 µm. The bar graphs represent LTR intensity measured using the Image J program (mean ± SEM, n = 9 or 15 different fields taken from ≥4 independent biological replicate experiments, ## p < 0.01 or #### p < 0.0001 for control, and ** p < 0.01 for EGF, analyzed by ANOVA with Dunnett’s post-hoc test). D Western blot analysis demonstrates the release of cathepsin B (CTSB) from lysosomes to the cytosol. Cytosolic proteins were extracted at 6 h after exposure to 40 µM zinc with or without EGF (100 ng/ml), MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The lower bar graph presents the band intensity ratio of mature CTSB to Actin (mean ± SEM, n = 6 or 3 independent biological replicate experiments, # p < 0.05, or #### p < 0.0001 for zinc, and * p < 0.05, ** p < 0.01, or **** p < 0.0001 for Zn + EGF, analyzed by ANOVA using Dunnett’s post-hoc test).
Compound 56, supplied by Mcule Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/compound+56/pmc11041518-165-19-34
Average 90 stars, based on 1 article reviews
compound 56 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
perfluorohexane (pfh, a fluorinated compound with a boiling point of 56 °c)  (Shanghai Macklin Biochemical)
90
Shanghai Macklin Biochemical perfluorohexane (pfh, a fluorinated compound with a boiling point of 56 °c)
A Bars represent LDH release at 20 hours after exposure to zinc (40 µM), with or without EGF (100 ng/ml), methyl-beta-cyclodextrin (MβCD, 2 mM; caveolin-dependent endocytosis inhibitor), chlorpromazine (CP, 2 µM; clathrin-dependent endocytosis inhibitor), compound 56 <t>(Cpd56,</t> 1 µM; inhibitor of EGFR tyrosine kinase activity), or ciliobrevin A (ciliob, 500 nM; dynein inhibitor) (mean ± SEM, n = 3-15 taken from ≥3 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or not significant (ns) for zinc, and ** p < 0.01 or *** p < 0.001 for Zn + EGF, analyzed using ANOVA with Dunnett’s post-hoc test). B Western blot analysis (upper) and quantitative graphs (lower) demonstrate the protein levels of EGFR and LAMP-1 at 0.5 hours after EGF (100 ng/ml) treatment with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The bar graphs indicate the band density ratio of EGFR or LAMP-1 to Actin (mean ± SEM, n = 4–8 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or ### p < 0.001 for control , and * p < 0.05 or ** p < 0.01 for EGF, analyzed by ANOVA using Dunnett’s post-hoc test). C Microscopic images (left) and quantitative graphs (right) show LTR-labeled neuronal cells at 1 h after EGF (100 ng/ml) treatment, with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). Scale bar: 100 µm. The bar graphs represent LTR intensity measured using the Image J program (mean ± SEM, n = 9 or 15 different fields taken from ≥4 independent biological replicate experiments, ## p < 0.01 or #### p < 0.0001 for control, and ** p < 0.01 for EGF, analyzed by ANOVA with Dunnett’s post-hoc test). D Western blot analysis demonstrates the release of cathepsin B (CTSB) from lysosomes to the cytosol. Cytosolic proteins were extracted at 6 h after exposure to 40 µM zinc with or without EGF (100 ng/ml), MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The lower bar graph presents the band intensity ratio of mature CTSB to Actin (mean ± SEM, n = 6 or 3 independent biological replicate experiments, # p < 0.05, or #### p < 0.0001 for zinc, and * p < 0.05, ** p < 0.01, or **** p < 0.0001 for Zn + EGF, analyzed by ANOVA using Dunnett’s post-hoc test).
Perfluorohexane (Pfh, A Fluorinated Compound With A Boiling Point Of 56 °C), supplied by Shanghai Macklin Biochemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/polybutylene+adipate+with+a+hydroxyl+number++ohv++of+56+1+mgkoh+g++pba+2000+/pmc11043469-30-3-18
Average 90 stars, based on 1 article reviews
perfluorohexane (pfh, a fluorinated compound with a boiling point of 56 °c) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
inhibitor of alk2 compound 56  (Novartis)
90
Novartis inhibitor of alk2 compound 56
A Bars represent LDH release at 20 hours after exposure to zinc (40 µM), with or without EGF (100 ng/ml), methyl-beta-cyclodextrin (MβCD, 2 mM; caveolin-dependent endocytosis inhibitor), chlorpromazine (CP, 2 µM; clathrin-dependent endocytosis inhibitor), compound 56 <t>(Cpd56,</t> 1 µM; inhibitor of EGFR tyrosine kinase activity), or ciliobrevin A (ciliob, 500 nM; dynein inhibitor) (mean ± SEM, n = 3-15 taken from ≥3 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or not significant (ns) for zinc, and ** p < 0.01 or *** p < 0.001 for Zn + EGF, analyzed using ANOVA with Dunnett’s post-hoc test). B Western blot analysis (upper) and quantitative graphs (lower) demonstrate the protein levels of EGFR and LAMP-1 at 0.5 hours after EGF (100 ng/ml) treatment with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The bar graphs indicate the band density ratio of EGFR or LAMP-1 to Actin (mean ± SEM, n = 4–8 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or ### p < 0.001 for control , and * p < 0.05 or ** p < 0.01 for EGF, analyzed by ANOVA using Dunnett’s post-hoc test). C Microscopic images (left) and quantitative graphs (right) show LTR-labeled neuronal cells at 1 h after EGF (100 ng/ml) treatment, with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). Scale bar: 100 µm. The bar graphs represent LTR intensity measured using the Image J program (mean ± SEM, n = 9 or 15 different fields taken from ≥4 independent biological replicate experiments, ## p < 0.01 or #### p < 0.0001 for control, and ** p < 0.01 for EGF, analyzed by ANOVA with Dunnett’s post-hoc test). D Western blot analysis demonstrates the release of cathepsin B (CTSB) from lysosomes to the cytosol. Cytosolic proteins were extracted at 6 h after exposure to 40 µM zinc with or without EGF (100 ng/ml), MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The lower bar graph presents the band intensity ratio of mature CTSB to Actin (mean ± SEM, n = 6 or 3 independent biological replicate experiments, # p < 0.05, or #### p < 0.0001 for zinc, and * p < 0.05, ** p < 0.01, or **** p < 0.0001 for Zn + EGF, analyzed by ANOVA using Dunnett’s post-hoc test).
Inhibitor Of Alk2 Compound 56, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/inhibitor+of+alk2+compound+56/pm37209681-866-21-20
Average 90 stars, based on 1 article reviews
inhibitor of alk2 compound 56 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


A Bars represent LDH release at 20 hours after exposure to zinc (40 µM), with or without EGF (100 ng/ml), methyl-beta-cyclodextrin (MβCD, 2 mM; caveolin-dependent endocytosis inhibitor), chlorpromazine (CP, 2 µM; clathrin-dependent endocytosis inhibitor), compound 56 (Cpd56, 1 µM; inhibitor of EGFR tyrosine kinase activity), or ciliobrevin A (ciliob, 500 nM; dynein inhibitor) (mean ± SEM, n = 3-15 taken from ≥3 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or not significant (ns) for zinc, and ** p < 0.01 or *** p < 0.001 for Zn + EGF, analyzed using ANOVA with Dunnett’s post-hoc test). B Western blot analysis (upper) and quantitative graphs (lower) demonstrate the protein levels of EGFR and LAMP-1 at 0.5 hours after EGF (100 ng/ml) treatment with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The bar graphs indicate the band density ratio of EGFR or LAMP-1 to Actin (mean ± SEM, n = 4–8 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or ### p < 0.001 for control , and * p < 0.05 or ** p < 0.01 for EGF, analyzed by ANOVA using Dunnett’s post-hoc test). C Microscopic images (left) and quantitative graphs (right) show LTR-labeled neuronal cells at 1 h after EGF (100 ng/ml) treatment, with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). Scale bar: 100 µm. The bar graphs represent LTR intensity measured using the Image J program (mean ± SEM, n = 9 or 15 different fields taken from ≥4 independent biological replicate experiments, ## p < 0.01 or #### p < 0.0001 for control, and ** p < 0.01 for EGF, analyzed by ANOVA with Dunnett’s post-hoc test). D Western blot analysis demonstrates the release of cathepsin B (CTSB) from lysosomes to the cytosol. Cytosolic proteins were extracted at 6 h after exposure to 40 µM zinc with or without EGF (100 ng/ml), MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The lower bar graph presents the band intensity ratio of mature CTSB to Actin (mean ± SEM, n = 6 or 3 independent biological replicate experiments, # p < 0.05, or #### p < 0.0001 for zinc, and * p < 0.05, ** p < 0.01, or **** p < 0.0001 for Zn + EGF, analyzed by ANOVA using Dunnett’s post-hoc test).

Journal: Cell Death & Disease

Article Title: An increase of lysosomes through EGF-triggered endocytosis attenuated zinc-mediated lysosomal membrane permeabilization and neuronal cell death

doi: 10.1038/s41419-024-07192-6

Figure Lengend Snippet: A Bars represent LDH release at 20 hours after exposure to zinc (40 µM), with or without EGF (100 ng/ml), methyl-beta-cyclodextrin (MβCD, 2 mM; caveolin-dependent endocytosis inhibitor), chlorpromazine (CP, 2 µM; clathrin-dependent endocytosis inhibitor), compound 56 (Cpd56, 1 µM; inhibitor of EGFR tyrosine kinase activity), or ciliobrevin A (ciliob, 500 nM; dynein inhibitor) (mean ± SEM, n = 3-15 taken from ≥3 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or not significant (ns) for zinc, and ** p < 0.01 or *** p < 0.001 for Zn + EGF, analyzed using ANOVA with Dunnett’s post-hoc test). B Western blot analysis (upper) and quantitative graphs (lower) demonstrate the protein levels of EGFR and LAMP-1 at 0.5 hours after EGF (100 ng/ml) treatment with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The bar graphs indicate the band density ratio of EGFR or LAMP-1 to Actin (mean ± SEM, n = 4–8 independent biological replicate experiments, # p < 0.05, ## p < 0.01, or ### p < 0.001 for control , and * p < 0.05 or ** p < 0.01 for EGF, analyzed by ANOVA using Dunnett’s post-hoc test). C Microscopic images (left) and quantitative graphs (right) show LTR-labeled neuronal cells at 1 h after EGF (100 ng/ml) treatment, with or without endocytosis inhibitors: MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). Scale bar: 100 µm. The bar graphs represent LTR intensity measured using the Image J program (mean ± SEM, n = 9 or 15 different fields taken from ≥4 independent biological replicate experiments, ## p < 0.01 or #### p < 0.0001 for control, and ** p < 0.01 for EGF, analyzed by ANOVA with Dunnett’s post-hoc test). D Western blot analysis demonstrates the release of cathepsin B (CTSB) from lysosomes to the cytosol. Cytosolic proteins were extracted at 6 h after exposure to 40 µM zinc with or without EGF (100 ng/ml), MβCD (2 mM), CP (2 µM), Cpd56 (1 µM), or Ciliob (500 nM). The lower bar graph presents the band intensity ratio of mature CTSB to Actin (mean ± SEM, n = 6 or 3 independent biological replicate experiments, # p < 0.05, or #### p < 0.0001 for zinc, and * p < 0.05, ** p < 0.01, or **** p < 0.0001 for Zn + EGF, analyzed by ANOVA using Dunnett’s post-hoc test).

Article Snippet: To inhibit the endocytosis of EGF receptor (EGFR), 2 mM methyl-beta-cyclodextrin (MβCD; Sigma-Aldrich), 2 µM chlorpromazine (CP; Sigma-Aldrich), 1 µM compound 56 (Cpd56; Merck), or 500 nM ciliobrevin A (Ciliob; GlpBio, Montclair, CA, USA) were administered as a 30-min pre-treatment before EGF treatment.

Techniques: Activity Assay, Western Blot, Control, Labeling